Amgen and Allergan today announced positive topline results of a combined phase 1 and phase 3 study evaluating ABP 798, a proposed biosimilar rituximab, in comparison with the reference Rituxan in patients with rheumatoid arthritis.
Amgen and Allergan today announced positive topline results of a combined phase 1 and phase 3 study evaluating ABP 798, a proposed biosimilar rituximab, in comparison with the reference Rituxan in patients with rheumatoid arthritis (RA).
The study enrolled 311 patients with RA to receive either ABP 798 (n = 104), US-sourced reference rituximab (n = 103), or EU-sourced reference rituximab (n = 104). The study’s duration was 48 weeks, and included a single transition for patients receiving the US-licensed reference to the proposed biosimilar.
The study’s primary endpoint was pharmacokinetic (PK) similarity between the reference and the proposed biosimilar. The PK endpoints evaluated were the area under the serum concentration—time curve and maximum serum concentration, and the drug makers state that both fell within the prespecified equivalence margin.
Equivalence in efficacy was measured by the change from baseline in Disease Activity Score in a count of 28 joints, measured with C-reactive protein, at week 24. According to Amgen and Allergan, “equivalent efficacy was established.” Furthermore, safety and immunogenicity were both similar among the 3 arms of the study.
“Results from this study show pharmacokinetic and clinical equivalence between ABP 798 and rituximab, further demonstrating Amgen's commitment to providing patients with access to high-quality, biological therapies,” said David M. Reese, MD, executive vice president of research and development at Amgen, in a statement. "We look forward to continuing to leverage our experience and expertise in biotechnology to bring more biosimilars to patients."
The companies noted that they are also currently undertaking another study intended to support regulatory applications; the second study is being conducted in patients with non-Hodgkin lymphoma.
If eventually approved, the biosimilar could compete not only with reference rituximab but also with Celltrion and Teva’s biosimilar, Truxima, which is now approved in both the United States and European Union (where it is also approved under the names Rituzena, Ritemvia, and Blitzima), and Sandoz’s biosimilar, approved in the European Union under the names Riximyo and Rixathon.
While it is not yet clear which indications Amgen and Allergan will seek for the biosimilar, if approved in inflammatory disease indications, ABP 798 could provide an option for US patients with inflammatory diseases who are not served by Truxima; when the biosimilar was approved in late 2018, it was only granted indications in oncology. According to a representative from Celltrion, the “skinny label” was a response to challenges in the patent landscape.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.